Nuvisertib received FDA fast track designation for intermediate or high-risk myelofibrosis, highlighting its potential to address unmet medical needs in this rare blood cancer. Preliminary phase 1/2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback